Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was  Recruiting
The University of Hong Kong
Fresienius Kabi HK Ltd
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
First received: November 21, 2007
Last updated: July 6, 2010
Last verified: July 2010
The primary purpose of this project is to investigate if addition of glutamine, an amino acid, to standard parenteral nutrition, may improve the clinical outcome of the bone marrrow transplantation reducing the occurrence of veno-occlusive disease and severity of mucositis.

Condition Intervention
Pulmonary Veno-Occlusive Disease
Hepatic Veno-Occlusive Disease
Drug: Glutamine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.

Resource links provided by NLM:

Further study details as provided by Hospital Authority, Hong Kong:

Primary Outcome Measures:
  • Veno-occlusive disease [ Time Frame: 1 month ]
  • Mucositis [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Hospital stay [ Time Frame: 2 months ]
  • Use of antibiotics [ Time Frame: 2 months ]

Estimated Enrollment: 40
Study Start Date: July 2004
Estimated Study Completion Date: June 2006

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Allogeneic bone marrow transplant recipients using busulfan and cyclophosphamide as conditioning.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00563498

Contact: YH Leung, Dr (852) 2855 3347 ayhleung@hku.hk

Queen Mary Hospital Recruiting
Hong Kong, China
Sub-Investigator: YH Leung, Dr         
Sub-Investigator: Raymond Liang, Prof         
Sponsors and Collaborators
Hospital Authority, Hong Kong
The University of Hong Kong
Fresienius Kabi HK Ltd
Principal Investigator: Albert Lie, Dr Department of Medicine/Division of Haematology, Queen Mary Hospital/ The University of Hong Kong
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00563498     History of Changes
Other Study ID Numbers: EC1432-00  HARECCTR0500034 
Study First Received: November 21, 2007
Last Updated: July 6, 2010
Health Authority: Hong Kong: Ethics Committee

Keywords provided by Hospital Authority, Hong Kong:
Veno-occlusive disease

Additional relevant MeSH terms:
Budd-Chiari Syndrome
Hepatic Veno-Occlusive Disease
Pulmonary Veno-Occlusive Disease
Cardiovascular Diseases
Digestive System Diseases
Embolism and Thrombosis
Gastrointestinal Diseases
Liver Diseases
Lung Diseases
Mouth Diseases
Respiratory Tract Diseases
Stomatognathic Diseases
Vascular Diseases
Venous Thrombosis

ClinicalTrials.gov processed this record on May 02, 2016